Olanzapine Dosing for Adults
For oral olanzapine, the therapeutic dose range is 5-20 mg/day, with a maximum of 20 mg/day for schizophrenia and bipolar disorder; for intramuscular olanzapine, the recommended dose is 10 mg per injection, with a maximum of 30 mg total daily dose (given as 3 doses of 10 mg each, spaced at least 2-4 hours apart). 1
Oral Olanzapine Dosing
Standard Therapeutic Dosing
- Starting dose: 5-10 mg/day
- Target therapeutic range: 10-20 mg/day
- Maximum approved dose: 20 mg/day 1
Special Populations
- Elderly patients: Start with 2.5-5 mg/day; maximum 10 mg/day 2, 3
- Debilitated patients or those predisposed to hypotension: Consider lower starting doses of 2.5-5 mg/day 1
Context-Specific Dosing
For chemotherapy-induced nausea/vomiting (CINV):
- High-emetogenic chemotherapy: 10 mg orally once before chemotherapy, then daily for 3 days (total 4 days) 4, 5
- Recent evidence suggests 2.5 mg/day may be equally effective with less sedation, particularly in elderly patients or those with breast cancer 6
- Breakthrough nausea/vomiting: 5-10 mg orally daily 4
For acute agitation in schizophrenia/bipolar disorder:
- Oral doses up to 40 mg/day have been studied in acute settings for the first 2 days, though this exceeds standard labeling 7
For Alzheimer's disease-related behavioral disturbances:
- Starting dose: 2.5-5 mg/day at bedtime
- Maximum: 10 mg/day 3
For delirium management:
- Starting dose: 2.5-5 mg orally or subcutaneously
- Usually given at bedtime; may repeat every 12-24 hours as needed 8
Intramuscular Olanzapine Dosing
Acute Agitation (Schizophrenia/Bipolar Mania)
- Recommended dose: 10 mg IM 1
- Alternative doses: 5 mg or 7.5 mg may be considered when clinical factors warrant 1
- Repeat dosing: Additional doses up to 10 mg may be given, but:
- Wait at least 2 hours after the first dose
- Wait at least 4 hours after the second dose
- Maximum total daily dose: 30 mg (three 10 mg injections) 1
Special Populations (IM)
- Elderly patients: 5 mg/injection 1
- Debilitated patients or those predisposed to hypotension: 2.5 mg/injection 1
- Older patients with acute agitation: 2.5 mg IM, with increments of 2.5 mg to maximum 7.5 mg at no closer than 30-minute intervals 2
Critical Safety Considerations
Maximal Dosing Precautions
Assess for orthostatic hypotension before administering subsequent IM doses, especially with maximal dosing (3 doses of 10 mg each, 2-4 hours apart), as this is associated with substantial risk of significant orthostatic hypotension 1. Do not administer additional doses to patients with clinically significant postural changes in systolic blood pressure 1.
Drug Interactions (IM)
- Do not combine with parenteral benzodiazepines for at least 2 hours after olanzapine IM administration due to risk of respiratory depression 2
- Do not mix in syringe with diazepam (causes precipitation) or haloperidol (degrades olanzapine) 1
- Lorazepam should not be used to reconstitute olanzapine for injection 1
Elderly-Specific Warnings
Olanzapine carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and should be used with extreme caution in this population 4, 1. When necessary, use the lowest effective doses (2.5-5 mg orally; 2.5 mg IM) 2, 3, 8.
Dose-Response Relationships
Research demonstrates that efficacy plateaus at doses above 10-15 mg/day, with minimal additional benefit at higher doses 9. The dose-response curve shows minimal rise in slope for doses exceeding 10 mg/day, and dopamine D2 receptor occupancy reaches the therapeutic threshold (65%) at approximately 12 mg/day 9.
Plasma concentration therapeutic range: 20-40 ng/mL (measured 12 hours post-dose) correlates with optimal D2-receptor occupancy (65-80%) and clinical response 10. However, only 35% of patients on doses of 2.5-20 mg/day achieve the suggested target range of 20-39 ng/mL, indicating significant inter-individual variability 11.
Practical Dosing Algorithm
- Start low: 5-10 mg/day orally (2.5-5 mg in elderly/debilitated)
- Titrate based on response: Increase to 10-15 mg/day if inadequate response after 1-2 weeks
- Consider plasma levels if: Non-response at 15 mg/day, suspected non-adherence, or potential drug interactions 9
- Doses >20 mg/day: Not routinely recommended; if considering, check plasma level first (target <60 ng/mL to minimize metabolic risks) 11
- For CINV: Use 10 mg/day (or 2.5 mg in elderly) for 4 days only; discontinue when symptoms resolve 6, 12